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Available online 4 May 2014Abstract The study of human cardiogenesis would benefit from a detailed cell lineage fate map akin to that established for
the haematopoietic lineages. Here we sought to define cell lineage relationships based on the expression of NKX2-5 and the cell
surface markers VCAM1, SIRPA and CD34 during human cardiovascular development. Expression of NKX2-5GFP was used to
identify cardiac progenitors and cardiomyocytes generated during the differentiation of NKX2-5GFP/w human embryonic stem
cells (hESCs). Cardiovascular cell lineages sub-fractionated on the basis of SIRPA, VCAM1 and CD34 expression were assayed for
differentiation potential and gene expression. The NKX2-5posCD34pos population gave rise to endothelial cells that rapidly lost
NKX2-5 expression in culture. Conversely, NKX2-5 expression was maintained in myocardial committed cells, which progressed
from being NKX2-5posSIRPApos to NKX2-5posSIRPAposVCAM1pos. Up-regulation of VCAM1 was accompanied by the expression of
myofilament markers and reduced clonal capacity, implying a restriction of cell fate potential. Combinatorial expression of
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173Cardiomyocyte lineage specificationmarkers identify specific stages of cardiomyocyte and endothelial lineage commitment and, thus provide a scaffold for
establishing a fate map of early human cardiogenesis.
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Human pluripotent stem cell (hPSC) derived cardiomyocytes
(CMs) are proving an invaluable resource for investigating
cardiac disease pathology and pharmaceutical evaluation and
as a model of human heart development (Burridge et al.,
2012; Itzhaki et al., 2011; Matsa et al., 2011; Moretti et al.,
2010; Murry and Keller, 2008; Sun et al., 2012). The adult
heart contains diverse cell lineages including cardiomyocytes
(both atrial and ventricular), smooth muscle cells, endothe-
lial cells, conduction system and interstitial mesenchymal
fibroblast cells. Prior work using mouse and human embryonic
stem cells (hESCs), which expressed fluorescent proteins
driven by the key cardiac transcription factors ISL1 (Bu et al.,
2009), MESP1 (Bondue et al., 2011) and NKX2-5 (Elliott et al.,
2011), demonstrated that a common precursor can give
rise to at least three lineages, cardiomyocytes, smooth
muscle and endothelial cells. Nevertheless, development of
a detailed cardiovascular cell fate map has been hindered
by a lack of cell surface markers to identify, and purify
progenitor populations and their mature derivatives (Martin-
Puig et al., 2008; Sturzu and Wu, 2011). However, identifi-
cation of cardiac associated cell surface proteins, such as
VCAM1 and SIRPA, provides an opportunity to address this
problem (Drukker et al., 2012; Dubois et al., 2011; Elliott et
al., 2011; Kattman et al., 2011; Uosaki et al., 2011; Yang et
al., 2008).
In the mouse, VCAM1 is essential for ventricular myogenesis
where it plays a role in mediating myocardial–epicardial
communication through interactions with α-4 integrin (Kwee
et al., 1995; Yang et al., 1995). Mice lacking VCAM1 die at
approximately day 12 of embryogenesis with multiple cardiac
lesions including reduced ventricular myocardium, disorganised
epicardium and septal defects (Kwee et al., 1995). By contrast,
CD34, which marks endothelial precursors (Ferreira et al.,
2007), is not required for cardiogenesis, with homozygous null
mouse mutants having only mildly impaired haematopoiesis
(Cheng et al., 1996). Similarly, heart development proceeds
normally in SIRPA knockout mice (Inagaki et al., 2000),
consistent with the observation that, unlike in humans,
SIRPA does not mark cardiac precursors in the developing
mouse (Dubois et al., 2011). Despite appearing to play no
functional role in heart development, SIRPA and CD34 are
valuable cell surface markers of emerging cardiovascular
lineages.
The highly conserved homeobox gene NKX2-5 is expressed
from the cardiac crescent stage of heart development and
is maintained in the myocardial lineages throughout life
(Harvey, 1996). Therefore, NKX2-5 expression can be used to
isolate cardiac progenitors, immature cardiomyocytes and
mature cardiomyocytes. In order to exploit NKX2-5's
temporally broad expression profile we have taken
advantage of the NKX2-5GFP/w hESC line, which expresses
GFP from the NKX2-5 locus (Elliott et al., 2011). Tofacilitate the identification and isolation of endothelial
precursors of the cardiac vasculature we have used the
cell surface protein CD34 (Costa et al., 2013; Ferreira et
al., 2007). In this study, we examined human cardiovas-
cular lineage specification based on the expression of
NKX2-5, and the cell surface markers SIRPA, VCAM1 and
CD34 in a human pluripotent stem cell differentiation
model system.
Materials and methods
hPSC culture and differentiation
hPSC culture and differentiation were performed as previ-
ously described. Briefly, at day 0 H3 NKX2-5GFP/w hESCs were
harvested and resuspended at 6 × 104 cells ml−1 in LI-APEL
medium (1 μg ml−1 insulin) (Ng et al., 2008) or StemDiff
APEL (Stem Cell Technologies) containing 20–40 ng ml−1 of
BMP4 (R&D Systems) and 20 ng ml−1 ACTIVIN A (R&D Systems),
30 ng ml−1 VEGF (PeproTech), 40 ng ml−1 SCF (PeproTech),
and 50 to 80 ng ml−1 WNT3A (Millipore). 50 μl of this cell
suspension was placed into each well of a 96 well round
bottomed non-adherent plate, and briefly centrifuged (3 min
at 480 g) to foster aggregate formation. At day 3, the
differentiation media was replaced with LI-APEL without
growth factors and at day 7 EBs were transferred to 10 cm
flat bottom tissue culture dishes in LI-APEL (APEL without
polyvinylalcohol) or LI-BEL (BSA used instead of recombinant
human albumin). The media was changed at day 10 and 14 of
EB development. Differentiations were terminated at day 21.
For negative control experiments NKX2-5GFP/w cells were
differentiated in FGF2 (PeproTech) at 100 ng ml−1 from day 0
to day 7 (Davis et al., 2008; Elliott et al., 2011; Goulburn et
al., 2011).
For monolayer differentiation (Lian et al., 2012) H3
NKX2-5GFP/w hESCs were expanded to 80% confluency on
Matrigel coated 6 well plates. At day 0, cells were treated
with RPMI (Corning) supplemented with B27 minus insulin
(1:50) and CHIR-99021 (8 μM; Tocris). At d1 the differenti-
ation media was replaced with RPMI supplemented with B27
minus insulin (Invitrogen). The media was changed at day 3
(RPMI/B27 minus insulin and 15 μM IWP-2 (Tocris)) and again
at day 5 (RPMI/B27 minus insulin). From d7 onwards cells
were maintained in RPMI/B27 minus insulin.
Flow cytometry
For flow cytometric analysis and sorting of live cells,
differentiated hESCs were dissociated with TrypLE Select
to form a single cell suspension. Antibody labelling of cells was
performed using anti-SIRPA (unconjugated or PE conjugated
forms, BioLegend), anti-VCAM1 (biotin-conjugated AbCam, APC
conjugated BioLegend), c-KIT (APC conjugated, BioLegend)
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anti-SIRPA antibodies were used at a concentration of 1:200
and all anti-VCAM1 antibodies were used at a concentration of
1:100. Samples were incubated with primary antibodies for
30 min, washed using FACS wash (PBS with 2% foetal calf
serum) and then incubated for a further 5 min at room
temperature (RT) or 30 min on ice with a 1:100 dilution of
the indicated secondary antibody. Non specific binding of
antibodies was blocked by incubation with mouse serum for
5 min at RT. Samples were subsequently incubated with
biotin-conjugated antibodies directed against SIRPA or VCAM1
for 5 min at RT or 30 min on ice. Following this, cells were
washed with FACS wash and incubated with Streptavidin R-PE
at a dilution of 1:300 for 5 min at RT or 30 min on ice. In
addition, control stains using non-specific antibodies (IgG) were
performed on both FGF control cultures and cardiac differen-
tiated cells. All antibodies were diluted and incubated in FACS
block. Analysis was performed using a FACSCalibur or Fortessa
flow cytometer. Cells were sorted from EBs for further analysis
using either a BD FACSDiva or Influx cell sorter (Monash
Flowcore). Data in the text are presented as mean percent-
age ± standard error of the mean of three independent
experiments.
Post-sort culture
For endothelial cell culture, isolated cells were grown on
fibronectin-coated (1 μg cm−2) tissue culture dishes in AEL
media supplementedwith 50 ng ml−1 VEGF (Costa et al., 2013).
Haematopoietic colony forming cell assays were performed as
previously described (Davis et al., 2008; Yu et al., 2012).
Briefly, sorted cell fractions were cultured in 1% methylcellu-
lose (Sigma) in APEL medium supplemented with 100 ng/ml
SCF, 50 ng/ml VEGF (PeproTech), 50 ng/ml IL-3 (PeproTech),
50 ng/ml APELIN-13 pyroglutamate (Sigma), and 4u/ml eryth-
ropoietin (PeproTech). 5000 cells/well were cultured in
triplicate and scored for colony growth after 9 to 11 days.
Clonal growth assays of sorted cells were performed using
the single cell deposition function of a FACSAria or a BD
Influx cell sorter (Monash Flowcore). Briefly, cells from
dissociated day 10 EBs were deposited at 1, 3, 10 or 30 cells
per well in 96 well plates. After 7 days in culture in LI-BEL
wells were scored for clones greater than 8 cells. Data shown
are the results of three independent experiments performed
in duplicate. For single cell clonal analysis cells were fixed
and stained as described (Immunohistochemistry).
Re-aggregates of cell fractions isolated by FACS on the
basis of GFP, SIRPA and VCAM1 expressions were formed by
centrifuging cells (for 5 min at 478 RCF) suspended in
LI-APEL media at 5000 cells per well of low-adherent U
bottom 96 well plates. After 4 days re-aggregates were
analysed by flow cytometry. Adherent cultures of cell
fractions from day 7 FACS experiments were formed by
plating 5000 cells per well of adherent flat bottom 96 well
plates in LI-APEL media. Adherent cultures were left for 7,
11 and 14 days until re-analysis.
Immunohistochemistry
Three cell fractions from day 10 EBs, GFP+posSIRPAposVCAM1pos
(GSVpos), GFPposSIRPAposVCAM1− (GSpos), and GFPnegVCAM1negSIRPAneg (triple negative), were used for immunofluorescence
experiments. Cells were fixed in 5% PFA in PBS for 5 min and
permeabilized using 0.1% Triton in PBS (5 minute incubation).
Non specific antibody staining was blocked by incubating
samples with 10% normal goat serum in PBS for 30 min at RT.
Cells were labelled with anti-cardiac troponin T type 2 (TNNT2)
(R&D systems) and anti-Calponin (CNN) (Abcam). Primary
antibodies were detected using an appropriate secondary
antibody conjugated to either Alexa-488 or Alexa-568. Cover-
slips were treated with ProLong Gold antifade + DAPI before
imaging. Imaging was performed on either a Zeiss Axiovert or
Nikon C1 confocal microscope (Monash Micro Imaging).
Ca2+ imaging
Three cell fractions from day 10 EBs, GFPposSIRPAposVCAM1pos
(GSVpos), GFPposSIRPAposVCAM1neg (GS+), and GFPnegVCAM1neg
SIRPAneg (TN), were used for functional analysis. These
fractions were plated onto FBS coated adherent flat-96-well
plates (4 wells per plate, 5000 cells per well) in LI-BEL media.
Cells were analysed at 3, 5 or 6 days post-plating. Cells were
treated with Flo 4 30 min prior to analysis. Ca2+ flux was
measured by the rate and pattern in fluorescence fluctuation
of individual cells. Cells displaying oscillating fluorescence
were considered to be spontaneous active (contractile). Each
cell was measured for 10 min to determine basal Ca2+ flux.
Subsequently, cells were treated with either 1 μM of isopro-
terenol, or an isoproterenol vehicle control and imaged for a
further 10 min.
Quantitative PCR
RNA was prepared using the High Pure RNA Isolation Kit
according to manufacturer's instructions (Roche). For quan-
titative real time PCR (Q-PCR), RNA samples were reverse
transcribed using SuperScript® III (Invitrogen) or ViLo
(Invitrogen)™ and relative gene expression levels deter-
mined by Taqman assays, as described (Davis et al., 2008).
Results
At day (d) 7 of hESC differentiation, a sub-population of
NKX2-5pos (i.e. GFPpos) cells expressing CD34 was identified
by flow cytometry (Fig. 1A, Supplementary Fig. 1A). CD34pos
cells emerge at the same time as NKX2-5pos cells, however,
most are GFPneg with only a small percentage co-expressing
GFP (Supplementary Fig. 1A). GFPposCD34pos cells expressed
high levels of the endothelial markers KDR, VWF, CD34, TIE2,
SCL (TAL1) and PECAM1, as did the GFPnegCD34pos fraction
(Fig. 1B). Conversely, expression of these markers was
substantially lower in all CD34neg cell types (Fig. 1B). How-
ever, consistent with observations in the mouse (Caprioli et
al., 2011), human NKX2-5posCD34pos cells expressed low
levels of GATA1 (Fig. 1B) and did not form blood colonies in
colony forming assays (not shown). In vascular growth
conditions (Costa et al., 2013) GFPposCD34pos derived cells
lost GFP expression but retained CD34 expression (N90%) and
frequently co-expressed KDR (69 ± 4.1%, n = 3). This expres-
sion profile for CD34 and KDR was mirrored in cells derived
from GFPnegCD34pos population (KDR, 70 ± 3.6%, n = 3;
Figure 1 NKX2-5posCD34pos cells are cardiac vascular progenitors. A) Flow cytometric analysis of GFP (i.e. NKX2-5) and CD34
identifies a GFPposCD34pos cell population (boxed—CD34pos). B) Quantitative PCR gene expression analysis of endothelial markers in
FACS isolated sub-populations (Rel. Exp. Lvl. = Expression relative to GFPnegCD34pos). C) GFPposCD34pos cells maintain CD34
expression and the majority of this population co-expresses KDR. Few KDR/CD34 cells emerge from CD34neg fractions. Numbers on
FACS plots are percentage of cells.
175Cardiomyocyte lineage specificationFig. 1C; Supplementary Fig. 1A). GFPposCD34pos derived cells
appeared morphologically similar to those arising from the
GFPnegCD34pos population. Both populations took up acety-
lated LDL (Supplementary Figs. 1B–E) consistent with an
endothelial cell phenotype.
During hESC differentiation, the onset of VCAM1 and
SIRPA expressions (Dubois et al., 2011; Elliott et al., 2011)
was contemporaneous with that of NKX2-5 (Fig. 2A). At d6
of differentiation, most NKX2-5pos cells were also SIRPApos
(Figs. 2A, B). By d10 of differentiation, two GFPpos populations
could be distinguished by flow cytometry; 47.7 ± 5.9% (n = 3)
were GFPposSIRPApos (hereafter referred to as GSpos) while the
remainder (44.9 ± 4.7%; n = 3) expressed NKX2-5, SIRPA andFigure 2 Temporal expression profile of VCAM1 and SIRPA during
expression during cardiac differentiation (A) in whole populations or (B
of GFPpos cells expressing SIRPA alone or SIRPA and VCAM1 (n = 3, ErroVCAM1 (hereafter GSVpos) (Figs. 2B, C). Unlike the mouse, a
bi-potent c-KitposNKX2-5pos cell population (Wu et al., 2006)
was not observed in differentiating hESCs (Supplementary
Fig. 2A). This is consistent with the finding that human
cardiovascular progenitors derive from c-KIT negative cells
(Yang et al., 2008). GSpos and GSVpos populations were
also observed in monolayer differentiations (Supplementary
Fig. 2B). By d14 59.7 ± 5.2% of GFPpos cells expressed SIRPA
and VCAM1 (Fig. 2C). Importantly, these markers and CD34 are
also expressed in differentiating iPSC cultures (Supplementary
Fig. 2C) (Dubois et al., 2011; Uosaki et al., 2011; Costa et
al., 2013). In addition, the SIRPApos population at day 6 of
differentiation contains a small population of CD34poscardiogenesis in differentiating hESCs. A, B) VCAM1 and SIRPA
) in analyses gated on GFPpos cells (shown in green). C) Percentage
r Bars, SEM).
176 R.J.P. Skelton et al.endothelial precursors and cultured SIRPApos cells give rise to
endothelial cells (Supplementary Figs. 2C–E).
To test the hypothesis that the GSpos cells represented a
precursor pool for the GSVpos population of committed CMs,
we characterized triple negative (i.e. negative for GFP,
SIRPA and VCAM1), GSpos and GSVpos cell populations isolated
by FACS at d10 of differentiation (Fig. 3A, Supplementary
Fig. 2C). Consistent with our hypothesis, the GSVpos popula-
tion predominantly comprised cardiac troponin T type 2
(TNNT2) positive CMs (84.2 ± 6.8%; n = 3; Fig. 2B, Supple-
mentary Fig. 2D). In contrast, a much lower percentage of the
d10 GS+ cells were TNNT2 positive (16.2 ± 4.6%; n = 3) and no
TNNT2 positive cells were observed in the triple negative
fraction (Fig. 2C). Similarly, analysis of contractility of single
cells 3 days post-sorting established that 76% of d10 + 3
GSVpos cells (49/64) were spontaneously contractile and
showed a calcium flux, whereas only 40% of the cells
derived from the GSpos population (26/64) displayed these
characteristics (Figs. 3C, D). However, after a further 2 days
in culture, the frequency of GSpos derived cells exhibiting
contractility approximated that seen for the GSVpos derivedFigure 3 Characterization of GSVpos and GSpos cell populations aris
outline (Neg, triple negative; GSpos, GFPposSIRPApos; GSVpos, GFPposSIRPA
50 μm) and percentage of TNNT2pos cells from three cell types as indicat
single CM. D) Percentage of GSpos and GSVpos cells displaying Ca2+ flux aft
cells from GSpos and GSVpos fractions (n = 3, Error Bars, SEM). F) Expressi
G–H) examples of CNN1+ and CNN1+TNNT2+ colonies (scalebar, 100 μmpopulations (Fig. 3D), suggesting that the former population
retained the capacity for ongoing differentiation. Whilst an
increasing percentage of the GSVpos CMs became isoproterenol
responsive between d10 + 3 and 10 + 6, only a small propor-
tion of GSpos derived cells responded to isoproterenol
stimulation (Supplementary Figs. 2E, F).
To examine the proliferative and differentiative capaci-
ties of the GSpos and GSVpos populations, we performed limit
dilution analysis to determine the clonogenic frequency of
single flow sorted cells (Elliott et al., 2011). Under these
adherent culture conditions, the GSpos cells had a clonal
frequency of 0.8% (~1/123) whilst 0.3% (~1/331) of the
GSVpos cells gave rise to clones (Fig. 3E). Neither fraction
gave rise to spontaneously contractile colonies, suggesting
that d10 NKX2-5pos CMs lack the capacity for either further
proliferation and/or differentiation in these conditions. In
order to assess the potential of these cells to proliferate and
differentiate, we used a clonal assay in which single cells
were seeded into each well of a 96 well plate. Analysis of
clones grown from single GSpos cells showed that of the 14
colonies (from 2784 cells deposited) 11 expressed the smoothing during cardiomyocyte differentiation in vitro. A) Experimental
posVCAM1pos). B) TNNT2 (red) and GFP (green) expressions (scalebar,
ed (n = 3, Error Bars, SEM). C) Representative Ca2+ flux in an isolated
er 3, 5 and 6 days post-FACS (n = 2). E) Frequency of colony forming
on of CNN1 and TNNT2 in colonies derived from single GSpos cells and
(G), 50 μm (H)).
Figure 4 Progression from a GSpos to a GSVpos phenotype. A–B) Brightfield (BF), green fluorescence (GFP) and overlay of d10 + 4 re-aggregates of GSpos (A) and GSVpos (B) fractions
obtained from d10 FACS (scalebar, 200 μm). C,D) Flow cytometric analysis of VCAM1 expression in GSpos and GSVpos fractions at d10 and at day 4 post aggregation (d10 + 4) (n = 3; Error
Bars, SEM). E) Diagram of cardiac cell lineage fate map during differentiation of hESCs.
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178 R.J.P. Skelton et al.muscle marker Calponin (CNN1), 2 were CNN1+TNNT2+ and 1
was TNNT2+ (Figs. 3F–H).
To ascertain if the GSVpos population was derived from
the GSpos population, cells representing each population
were flow sorted, re-aggregated and cultured as contractile
cardiospheres (Figs. 4A, B; Supplementary Video 1).
After 4 days, the majority of GSpos cells had become GSVpos
(75 ± 7.2%; n = 3) whilst almost all GSVpos cells retained
marker expression (Figs. 4C, D). Taken together these data
support the hypothesis that GSpos (i.e. NKX2-5posSIRPApos)
precursors display greater proliferative capacity and can
form smooth muscle cells and CMs whilst GSVpos (i.e.
NKX2-5posSIRPAposVCAM1pos) cells consist mainly of commit-
ted CMs (Fig. 4E).
Discussion
The cell surface markers SIRPA, VCAM1 and CD34, were used
to isolate and characterize cardiac precursor populations of
the endothelial and myogenic lineages (Fig. 4E). The NKX2-5pos
CD34pos fraction corresponded to emerging cardiac endothelial
precursors, defined by the transient expression of NKX2-5
during their early development. NKX2-5posSIRPAposVCAM1pos
cardiomyocytes arose from an NKX2-5posSIRPApos intermedi-
ate, demonstrating a lineage relationship between these two
cell populations and establishing VCAM1 up-regulation as a key
marker of cardiomyogenic commitment. Further, recent work
suggests that VCAM1 has utility as a definitive cardiomyocyte
marker in mice (Pontén et al., 2013). At present, it is difficult
to correlate our in vitro findings with the in vivo expression
pattern of these markers since those studies require human
embryos between 3 and 4 weeks of gestation. We have
previously shown that transcripts for both SIRPA and VCAM1
are expressed at high levels in foetal hearts at 9 weeks
suggesting that these markers are expressed in vivo (Elliott
et al., 2011). Nevertheless, given that mouse models are
inadequate for establishing human protein expression profiles,
as demonstrated for c-KIT here and previously for SIRPA
(Dubois et al., 2011), obtaining experimental data from early
human embryos is a future priority.
Molecular markers permitting the identification and
isolation of distinct cardiogenic cell populations will be
useful for understanding the developmental logic of human
cardiogenesis, pharmaceutical screening and regenerative
medicine (Burridge et al., 2012; Sturzu and Wu, 2011;
Thavandiran et al., 2013; Tiscornia et al., 2011). In this
context, the temporal and contingent relationships of the
cell lineage markers described here form a foundation for
placing newly identified markers within the cardiovascular
lineage fate map. Subsequently, specific marker combina-
tions could be used to isolate and study, in a manner
analogous to the haematopoietic system, homogenous,
well-defined, cardiac cell populations.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2014.04.016.
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